Medacta Group stock
Price history
−32.53% over the period1 year: from CHF 150.00 (November 20, 2025) to CHF 101.20 (November 20, 2026), −32.53%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | CHF 101.20 |
| October 30, 2026 | CHF 117.60 |
| September 30, 2026 | CHF 114.20 |
| August 31, 2026 | CHF 126.20 |
| July 31, 2026 | CHF 132.00 |
| June 30, 2026 | CHF 136.00 |
| May 29, 2026 | CHF 143.20 |
| April 30, 2026 | CHF 141.60 |
| March 31, 2026 | CHF 149.60 |
| February 27, 2026 | CHF 159.40 |
| January 30, 2026 | CHF 165.20 |
| December 30, 2025 | CHF 156.40 |
| November 28, 2025 | CHF 154.80 |
| November 20, 2025 | CHF 150.00 |
At a glance
The company
Develops, manufactures and distributes orthopedic and neurosurgical medical devices globally
Latest results
Quarter to June 30, 2026 · EPS €2.10
TickerLandia's take on Medacta Group
- Priced in line with similar companies: trailing 12-month P/E 28 vs 29 (−4%) in a group of 10.
- Strong point: Earnings stability (68/100 in its group). Weak point: Market momentum (7/100).
- “Most upside for analysts” (Switzerland): No. 6 of 57.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−42.89% from the 52-week high
Analysts · 6 analysts
Average targetCHF 149.05+47.28% vs. price
Buy 4 · Hold 2 · Sell 0 · Buy
TickerLandia Fingerprint: Medacta Group
Compared with similar companies: very weak momentum and very high risk.
Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Priceaverage43
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 13.5 25 Price/book 4.51 56 Forward P/E 19.9 52 Price/sales 2.85 34 P/E (trailing 12 months) 27.7 47 Profitabilityaverage56
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 15.2% 44 ROE 17.0% 69 Gross margin 65.5% 53 ROA 7.2% 56 Net margin 10.9% 60 Earnings stabilityhigh68
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.3% 79 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 56 Growthaverage48
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +16.09% 82 Revenue growth (year over year) +7.00% 40 Earnings growth (year over year) −30.20% 21 Financial strengthaverage42
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.34 35 Interest coverage 16.9 45 Current ratio 2.10 60 Debt/equitycounts in reverse: lower means more financial strength 0.66 27 Dividendlow23
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 1.1% 26 Consecutive dividend years 5 years 26 Payout ratio 30.1% 16 Market momentumvery weak7
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −22.41% 7 Relative strength (6 months) −36.09% 6 1-year return −32.53% 6 Distance from 200-day average −24.69% 7 Riskvery high81
How much the price swings.
Metric Value Position in group Volatility (60 days) 39.1% 80 Beta (1 year) 1.03 74 Maximum drawdown (12 months) 42.5% 89
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Medacta Group is in line with similar companies
Medacta Group's P/E (trailing 12 months): 27.7, in line with the median of a group of 10 similar companies (28.9).
Compared with 10 similar companies
| Metric | Medacta Group | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 27.7 | Middle | |
| Forward P/E | 19.9 | Middle | |
| Operating margin | 15.2% | Middle | |
| ROE | 17.0% | Middle | |
| Debt/equity | 0.66 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Medacta Group. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€368.17M
Latest quarter · Q2 2026
Net income
€41.86M
Latest quarter · Q2 2026
Quarterly net margin
11.4%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- CHF 2.02B
- P/E
- 27.7
- EPS
- CHF 3.65
- Volume
- 24.75K
- Daily trading
- €4.83M
- Dividend yield
- 1.09%
- Last ex-dividend on May 7, 2026
How Medacta Group is changing
All resultsRevenue grew 17.7% a year on average over the last 5 years
Less cash than profit: free cash flow equal to 25% of net income
Revenue has grown for 5 fiscal years in a row
Returns
Medacta Group returns with dividends
CHF 1,000 invested in Medacta Group 5 years ago, on November 22, 2021, would be worth CHF 748 today with dividends reinvested: −25.21% in total, −5.65% per year. On price alone it would be CHF 728 (−27.19%).
| Period | Medacta Group | SMI | CHF 1,000 becomes |
|---|---|---|---|
| 1 month | −12.91% | +0.65% | CHF 871 |
| 6 months | −30.49% | +8.75% | CHF 695 |
| Year to date | −35.29% | +9.83% | CHF 647 |
| 1 year | −32.00% | +16.18% | CHF 680 |
| 3 years | −12.28% | +35.68% | CHF 877 |
| 5 years | −25.21% | +16.48% | CHF 748 |
Over the last 6 months it has done better than 3% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment
The chart in detail
Medacta Group: technical analysis
Medacta Group is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 42.5% below its all-time closing high (CHF 176.00, January 23, 2026).
- Trend
- Downward
- RSI (14 sessions)
- 29
- Below 30: a strong fall in a short time
- vs 200-session average
- −24.69%
Active signals
New 52-week low.
since November 19, 2026
Close below the low of the previous 55 sessions.
since November 19, 2026
RSI below 30: the stock has fallen a lot in a short time.
Support and resistance
Price areas where Medacta Group has stopped several times in the last year. They describe the chart; they are not forecasts.
- ResistanceCHF 139.10+37.45%2 touches, last on July 30, 2026
- ResistanceCHF 132.93+31.36%3 touches, last on September 4, 2026
- ResistanceCHF 128.67+27.14%3 touches, last on July 21, 2026
- Last priceCHF 101.20
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved roughly in line with the SMI.
- Beta (1 year) vs SMI
- 1.03
- Volatility (60 sessions, annualised)
- 39.1%
- Largest fall in the last year
- −42.50%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Medacta Group: seasonality
Average monthly price change over 8 years
Over the last 8 years, the strongest month for Medacta Group has been April: +6.51% on average, positive in 5 years out of 7. The weakest has been March: −6.91% on average, positive in 0 years out of 7. November, the current month, has been positive in 5 years out of 7 (+3.50% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +3.01% | +5.63% | 5 of 7 |
| February | +1.17% | −1.18% | 3 of 7 |
| March | −6.91% | −3.66% | 0 of 7 |
| April | +6.51% | +5.38% | 5 of 7 |
| May | +2.75% | +1.24% | 5 of 8 |
| June | −2.33% | −1.34% | 2 of 8 |
| July | +4.34% | +3.62% | 6 of 8 |
| August | −1.36% | −2.17% | 3 of 8 |
| September | −2.03% | −1.31% | 4 of 8 |
| October | −1.34% | +0.48% | 4 of 8 |
| November | +3.50% | +4.09% | 5 of 7 |
| December | +0.58% | +1.51% | 5 of 7 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Medacta Group and its competitors
Medacta Group SA serves customers in Latin America, North America, the Asia-Pacific region, and the Middle East and Africa with orthopedic and neurosurgical medical devices. The company develops, manufactures and distributes these products, and it complements them with personalized 3D planning tools for hip, knee and shoulder joint replacement, sports medicine and spine surgery. Its offering thus combines physical devices with digital planning tools used before surgery.
- Headquarters
- Castel San Pietro, Switzerland
- Employees
- 2,273
- Founded
- 1958
- Chief executive
- Francesco Siccardi
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Medacta GroupMOVE | $2.41B | 15.2% | 27.7 | −30.49% |
| ElektaEKTA.B | $2.27B | 9.2% | — | +1.17% |
| GN Store NordGN | $2.46B | 10.9% | 90.2 | +22.10% |
| ChemoMetecCHEMM | $1.75B | 49.1% | 59.9 | +99.42% |
| AmbuAMBU.B | $3.4B | 13.2% | 36.7 | +32.33% |
| El.En.ELN | $1.44B | 14.7% | 20.7 | +10.78% |
Same industry or related industries, similar size. Compare Medacta Group with its competitors · Full profile
